Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Metastasis is a primary cause of death in small-cell lung cancer (SCLC).
• Understanding SCLC metastasis mechanisms is crucial for improving clinical outcomes.
• Identifying key regulators of SCLC metastasis can reveal therapeutic targets.

Purpose of the Study:

• To identify key molecular regulators of SCLC metastasis.
• To elucidate the mechanism by which identified regulators control metastasis.
• To explore potential therapeutic strategies based on these findings.

Main Methods:

• Genome-scale screening using pooled CRISPR/Cas9 library in mouse SCLC models.
• Analysis of Cullin5 (CUL5) and suppressor of cytokine signaling 3 (SOCS3) function.
• Investigation of integrin β1 degradation and downstream signaling pathways (FAK/SRC).
• Correlation analysis with clinical patient data (n=128).

Main Results:

• CUL5 and SOCS3 were identified as top candidates regulating SCLC metastasis.
• Deficiency in CUL5 or SOCS3 impairs E3 ubiquitin ligase complex formation, preventing integrin β1 degradation.
• Stabilized integrin β1 activates FAK/SRC signaling, promoting SCLC metastasis.
• Low CUL5/SOCS3 expression correlated with high integrin β1 and poor prognosis in SCLC patients.
• CUL5-deficient SCLC showed vulnerability to SRC inhibitor dasatinib.

Conclusions:

• CUL5 and SOCS3 are essential for regulating integrin β1 turnover in SCLC.
• The CUL5/SOCS3-integrin β1 axis plays a critical role in SCLC metastasis.
• Targeting this pathway, potentially with SRC inhibitors like dasatinib, may offer therapeutic benefits for SCLC patients.